

1 **Title Page**

2 **GENDER DIFFERENCES IN ANTIBIOTICS USE BEHAVIOUR AND ACCESS TO ANTIBIOTICS IN**  
3 **LOW- AND MIDDLE-INCOME COUNTRIES: A SCOPING REVIEW PROTOCOL**

4

5 **Authors:** Oluwafemi J. Adewusi<sup>1\*</sup>, Rebecca Cassidy<sup>1</sup>, Aaron O. Aboderin<sup>2</sup>, Simon Bailey<sup>1</sup>, and  
6 Sarah Hotham<sup>1</sup>

7

8 **Affiliations**

9 <sup>1</sup>Centre for Health Services Studies, University of Kent, Canterbury, England

10 <sup>2</sup>Department of Medical Microbiology and Parasitology, College of Health Sciences, Obafemi  
11 Awolowo University, Ile-Ife, Nigeria

12

13

14 **\*Corresponding author email:** [oa459@kent.ac.uk](mailto:oa459@kent.ac.uk)

15

16

17 **Author contributions**

18 **Conceptualization:** Oluwafemi J. Adewusi

19 **Methodology:** Oluwafemi J. Adewusi, Rebecca Cassidy, Sarah Hotham,

20 **Supervision:** Rebecca Cassidy, Aaron O. Aboderin and Sarah Hotham

21 **Writing (Original draft):** Oluwafemi J. Adewusi

22 **Writing (review and editing):** Rebecca Cassidy, Simon Bailey, Aaron O. Aboderin and Sarah  
23 Hotham

24 **Approval of manuscript:** All the authors

25

26 **Funding**

27 The study received no funding.

28

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29        **GENDER DIFFERENCES IN ANTIBIOTICS USE BEHAVIOUR AND ACCESS TO ANTIBIOTICS IN**  
30                    **LOW- AND MIDDLE-INCOME COUNTRIES: A SCOPING REVIEW PROTOCOL**

31        **ABSTRACT**

32        **Background:** In low-and middle-income countries (LMICs), the persistent lack of access and  
33        high inappropriate use of antibiotics, which are fuelled by gender-related factors continue to  
34        facilitate antimicrobial resistance which in turn reduces the capacity to treat infectious  
35        diseases. However, there is lack of sufficient clarity on the nature and extent of gender  
36        influence on access to antibiotics and antibiotic use behaviour. This proposed study aims to  
37        systematically review available literature in order to map out the nature and extent of  
38        evidence on gender differences and related factors influencing antibiotics use behaviour and  
39        access to antibiotics in LMICs.

40        **Methods:** This scoping review will be conducted using the Preferred Reporting Items for  
41        Systematic Reviews and Meta-Analyses (PRISMA) guidelines for scoping reviews. The  
42        MEDLINE, PsycINFO, African Journal Online (AJOL), Web of Science and CINAHL databases will  
43        be searched for peer-reviewed articles and relevant electronic grey literature will also be  
44        included in the study. A predefined excel spreadsheet will be utilized for data extraction and  
45        analysis. Findings will be presented in narrative summary and tables.

46        **Conclusion:** It is expected that this study will identify knowledge and gaps on gender  
47        contributory factors to antibiotics use and access to antibiotics. These will contribute to  
48        understanding gender health inequalities and areas for further research on gender  
49        mainstreaming in antimicrobial stewardship efforts in the LMICs. This study findings will be  
50        disseminated through presentations in scientific conferences and publications in peer-  
51        reviewed journals.

52 **Scoping review registration with Open Science Framework:** Registration DOI:

53 <https://doi.org/10.17605/OSF.IO/N5W8E>

54 **Keywords:** antibiotics use behaviour, antibiotic access, gender, LMICs

55

56

57

58

59

## 60 INTRODUCTION

61 The rates of antimicrobial resistance (AMR) are increasing worldwide especially in low-and  
62 middle-income countries (LMICs) (1), resulting into the use of broad-spectrum antibiotics  
63 including those considered as last resort for the treatment of bacterial infections (2). This  
64 leaves clinicians with limited therapeutic options for the treatment of infections, and also  
65 potentially signifies future inability to treat infections. Apart from the clinical implications,  
66 AMR will significantly increase healthcare cost, poverty (3) and the World Bank predicted a  
67 100 trillion USD global production loss by 2050 if there are no AMR policy interventions (4).

68 Notably, AMR is fuelled largely by modifiable human behaviour, primary of which is  
69 inappropriate or irrational antibiotics use (1). As evidenced from growing literature, antibiotics  
70 use behaviour change is complex and non-linear (1). This is reflected in the dynamics around  
71 self-medication (5), non-adherence to medical prescription (6) and use of antibiotics for viral  
72 infections (7). The complexities in antibiotic use behaviour are fuelled by factors such as the  
73 lived experience of illness, social perception of antibiotics, access and cost of antibiotics, and  
74 societal expectation of disease treatment (8). Previous studies also showed that inappropriate  
75 antibiotics behaviour in the LMICs is associated with income, level of education, perception of  
76 illness and antibiotics, sex and other cultural related issues including gender (6)(5)(9).

77 Despite the increasing use of antibiotics, there are reported inequity gaps in access to this  
78 medicine. The Centre for Disease Dynamics, Economics and Policy (CDDEP) reported in 2019  
79 that LMICs had limited access to antibiotics compared to their HICs counterparts and these  
80 were attributed to patients' financial incapability, limited resource allocations to health by the  
81 government and poor local and international drug logistics and infrastructure. The report  
82 revealed that dying from treatable microbial infections due to lack of access to adequate

83 antibiotics indirectly fuel antimicrobial resistance through death from treatable bacterial  
84 infections which further create a cycle of ineffective antibiotics use (10).

85 The contributions of gender to health are well documented, playing crucial direct and indirect  
86 dynamic roles in disease perceptions, prevention practices, health-seeking behaviour and  
87 treatment, and access to healthcare (11)(12). Although the pattern of gender inequalities  
88 varies according to context, women are largely affected due to the patriarchy systems in most  
89 LMICs. They often lack economic resources, incapable of independently taking health  
90 decisions and hence, unable to access needed healthcare (13). For instance, with 26% poverty  
91 incidence and 17% access to healthcare services among women-headed households  
92 compared to 24% poverty incidence and 41% access to healthcare services among male-  
93 headed households in Nigeria (14)(15), the risk of exposure to resistant infections and  
94 inappropriate antibiotics use behaviour are higher for women and needless to say that this  
95 further sustains the vicious cycle of poverty and inequalities (16).

96 Results from past studies also indicated that women were 1.65 times more likely to be infected  
97 with resistant pneumonae infection largely because of motherhood roles (17) and that poor  
98 hand hygiene practices during childbirth also predispose them to resistant infections (11). In  
99 addition, experience of being labelled promiscuous and ‘wayward’ by the health workers  
100 when suffering from sexual health and urinary tract infections could make women resort to  
101 self-medication with antibiotics (18).

102 In spite of the reportedly high prevalence of inappropriate use of antibiotic across different  
103 categories of the population in the LMICs, most of these countries lack policies or guidelines  
104 strategically addressing access to antibiotics and inappropriate use behaviour with  
105 consideration to gender. Increasing access to antibiotics will not only reduce death due to

106 bacterial infections, it will also prevent AMR. Hence, the importance of addressing gender  
107 inequalities in access to this medicine as well as in antibiotics use behaviour.

108 Most existing reviews on human antibiotics behaviours focused on physicians' prescribing  
109 behaviour (19)(20) and other studies examined users' behaviour (21)(9) with no gender  
110 reference thus creating a gap in the knowledge of the gender-related determinants of  
111 antibiotics use. Similarly, there is little evidence on how gender factors influence access to  
112 antibiotics, and it is against this backdrop that we aimed to conduct a scoping review. We  
113 intend to utilize this scoping review to examine the range and characteristics of evidence  
114 available in the literature as well as knowledge gap on the gender differences in antibiotics  
115 use behaviour and access to antibiotics in the LMICs.

#### 116 **Main objective:**

117 The overarching aim of this review is to systematically identify the nature, themes and  
118 knowledge gaps on antibiotics use behaviour and access to antibiotics with reference to  
119 gender in LMICs.

#### 120 **Review questions**

- 121 1. What gender differences in antibiotic use exist in the LMICs?
- 122 2. What factors contribute to the gender differences in antibiotic use behaviour in the  
123 LMICs?
- 124 3. What gender differences in access to antibiotic exist in the LMICs?
- 125 4. What factors contribute to the gender differences in access to antibiotic in the  
126 LMICs?

127

128

129

**Table 1: Guiding PICOS framework for the study question**

<b>Criteria</b>	<b>Determinants</b>
Population	Male and females
Interventions	Antibiotic access, Antibiotic use behaviour
Comparison	Not applicable
Outcomes	Infection risk factors, perceptions and lived experiences of infectious diseases, knowledge, attitude, practice (KAP) of antibiotic of antibiotics use
Setting	Low- and middle-income countries

130

131

## 132 **METHODOLOGY**

### 133 **Protocol and registration**

134 The study protocol was registered with the Open Science Framework with registration digital  
135 object identifier: <https://doi.org/10.17605/OSF.IO/N5W8E>.

### 136 **Search strategy**

137 This review will be conducted to follow the Preferred Reporting Items for Systematic Reviews  
138 and Meta-Analyses (PRISMA) guidelines for scoping review (22). The review will be conducted  
139 between June and December 2023. The MEDLINE, PsycINFO, African Journal Online (AJOL),  
140 Web of Science and CINAHL databases would be searched for peer-reviewed primary studies  
141 relevant to the study research questions. Grey literature such as technical reports from  
142 organizations working on antibiotics use in the LMICs will also be included. Additional  
143 publications will be checked from the reference lists of relevant articles using snowballing  
144 technique. Authors of relevant papers would also be emailed for access to non-readily  
145 available and additional relevant papers. No date or periodic coverage limitation would be  
146 applied to the search.

147

148

### 149 **Search terms**

150 In this study, ‘access’ refers to affordability and availability of antibiotics. These are hinged on  
151 two of the four blocks within the WHO framework for access to medicine. These two blocks  
152 (affordable prices and reliable health and supply systems) were selected because they relate  
153 more with the consumers as other blocks (Rational selection and sustainable financing) rely  
154 largely on the health system (23). Therefore, this study considers financial and economic  
155 capability to purchase as well as availability of needed antibiotics.

156 Keywords to be used for the search will include ‘antibiotic use’, ‘antimicrobial use’,  
157 ‘respiratory tract infections’, ‘diarrhoea’, ‘anti-bacterial/anti-infective agents’, ‘prudent  
158 antibiotic use’, ‘judicious antibiotic use’, ‘self-medication’, ‘practice’, ‘access\*’, ‘afford\*’,  
159 ‘gender’, ‘male’, ‘female’, ‘Africa’, ‘sub-Sahara’, ‘Asia’, ‘low-and middle-income countries’.

### 160 **Inclusion and exclusion criteria**

161 The literature search will be limited to literature with the following criteria:


- 162 • primary peer and non-peer reviewed publications in English language
- 163 • studies reporting antibiotics use among males and females
- 164 • studies reporting antibiotics access among males and females
- 165 • studies conducted in LMICs (as defined by the World Bank (24))
- 166 • all study designs

167 Studies with the following criteria will be excluded:



- 168       • Studies published as conference abstracts reviews, editorials or letters to the editor on
- 169            AMU
- 170       • studies reporting antibiotics use in animals
- 171       • studies describing antibiotics prescribing behaviour and factors
- 172       • studies generally reporting antibiotics use without reference to males or females
- 173       • Studies conducted in high income countries
- 174

175 **Figure 1: Flow diagram for the scoping review methodology on gender differences in**  
176 **antibiotics use behaviour and access to antibiotics in LMICs**



194

195 **Data extraction/variables of interest**

196 Data extraction will be carried out from all eligible articles using a predefined excel sheet, by  
197 the first author with supervision from all the other senior authors. The following variables will  
198 be extracted from the reviewed studies; title, author, year of publication, target population

199 and characteristics, country of study, study setting, study design, sample size, gender factors  
200 affecting antibiotic access, gender factors affecting antibiotic use practices and behaviour.

### 201 **Data charting and results presentation**

202 The extracted data will be organized in an excel spreadsheet and descriptive analysis will be  
203 carried out to characterise the studies. A thematic analysis would also be carried out on the  
204 review findings, and these will be presented in tables and charts where appropriate. The study  
205 findings will be summarized in narrative that synthesize the results across the data variables,  
206 themes and knowledge gaps with possible implications for further studies.

### 207 **Ethical consideration**

208 This would not be applicable to this study.

### 209 **CONCLUSION**

210 While there are increasing studies outlining the factors influencing access and antibiotics use  
211 behaviour in LMICs, there are limited evidence the gender dynamics of these factors. This  
212 scoping review will map out evidence on the gender differences on access and antibiotics use  
213 behaviour in LMICs. The dissemination plan for the findings of this review include seminar  
214 presentations at the University and local public health institutions, conference presentations  
215 and publication in peer-reviewed journals.

216

217

## 218 **References**

- 219 World Health Organization. Worldwide country situation analysis: response to antimicrobial  
220 resistance. World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. 2015. Available  
221 from: <http://www.who.int/drugresistance/documents/situationanalysis/en/>
- 222 Abubakar U. Antibiotic use among hospitalized patients in northern Nigeria: a multicenter point-  
223 prevalence survey. *BMC Infect Dis.* 2020;20(1):86.
- 224 The World Bank. World. By 2050, drug-resistant infections could cause global economic damage on  
225 par with 2008 financial crisis. 2016. Available from: [https://www.worldbank.org/en/news/press-  
226 release/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-  
227 with-2008-financial-crisis](https://www.worldbank.org/en/news/press-release/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-with-2008-financial-crisis)
- 228 O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. 2016.
- 229 Esan DT, Fasoro AA, Odesanya OE, Esan TO, Ojo EF, Faeji CO. Assessment of Self-Medication Practices  
230 and Its Associated Factors among Undergraduates of a Private University in Nigeria. *J Environ Public  
231 Health.* 2018;2018.
- 232 Kehinde OO, Ogunnowo BE. The pattern of antibiotic use in an urban slum in Lagos State, Nigeria. *West  
233 African Journal of Pharmacy.* 2013;24(1):49–57. Available from:  
234 [http://www.wapharm.org/wajp/admin/12389900798187/wajp\\_2013\\_24\\_1\\_5.pdf.pdf](http://www.wapharm.org/wajp/admin/12389900798187/wajp_2013_24_1_5.pdf.pdf)
- 235 Salihu Dadari HI. Antibiotics use, knowledge and practices on antibiotic resistance among  
236 breastfeeding mothers in Kaduna state (Nigeria). *J Infect Public Health.* 2020 Dec 1;13(12):2072–9.
- 237 Davis MD, Lohm D, Flowers P,, Whittaker A. Antibiotic assemblages and their implications for the  
238 prevention of antimicrobial resistance. *Soc Sci Med.* 2022 [cited 2022 Dec 7];315(115550). Available  
239 from: <https://www.sciencedirect.com/science/article/abs/pii/S0277953622008565>
- 240 Torres NF, Chibi B, Middleton LE, Solomon VP, Mashamba-Thompson TP. Evidence of factors  
241 influencing self-medication with antibiotics in low and middle-income countries: a systematic scoping  
242 review. *Public Health [Internet].* 2019;168:92–101. Available from:  
243 <https://doi.org/10.1016/j.puhe.2018.11.018>
- 244 Frost I, Craig J, Joshi J, Faure K, Laxminarayan R. Access Barriers to Antibiotics. Washington D.C.; 2019  
245 [cited 2023 Jan 31]. Available from: [https://onehealthtrust.org/wp-content/uploads/2019/04/access-  
246 barriers-to-antibiotics.pdf](https://onehealthtrust.org/wp-content/uploads/2019/04/access-barriers-to-antibiotics.pdf)
- 247 Ukwaja KN, Alobu I, Nweke CO, Onyenwe EC. Healthcare-seeking behavior, treatment delays and its  
248 determinants among pulmonary tuberculosis patients in rural Nigeria: a cross-sectional study. *BMC  
249 Health Serv Res.* 2013;13(25):1–9.
- 250 Azuh D, Fayomi O, Ajayi, Lady. Socio-Cultural Factors of Gender Roles in Women's Healthcare  
251 Utilization in Southwest Nigeria. *Open J Soc Sci.* 2015;03(04):105–17.

- 2152 Barasa V. WaArusha Agro-pastoralist Experiences with risk of febrile illness: an ethnographic study of  
2153 social drivers of zoonoses and rural health-seeking behaviours in Monduli district, Northern Tanzania.  
2154 PhD Thesis, University of Sussex; 2019.
- 2156 Akerele D, Momoh S, Adewuyi SA, Phillip BB, Ashaolu OF, Akerele D. Socioeconomic determinants of  
2156 poverty among urban households in South-West Nigeria. *Int J Soc Econ*. 2013;39(3):168–81.
- 2157 Omonona BT, Obisesan AA, Aromolaran OA. Health-care access and utilization among rural households  
2158 in Nigeria. *J Dev Agric Econ*. 2015;7(5):195–203.
- 2159 van der Heijden M, Sandgren A, Pránting M, Karvanen M, Aagaard H, Zorzet A, et al. When the Drugs  
2160 Don't Work: Antibiotic Resistance as a Global Development Problem. *ReAct*. Uppsala, Sweden; 2019.  
2161 Available from: [https://www.daghammarskjold.se/wp-content/uploads/2019/02/amr-sdg-report-](https://www.daghammarskjold.se/wp-content/uploads/2019/02/amr-sdg-report-final_inter2.pdf)  
2162 [final\\_inter2.pdf](https://www.daghammarskjold.se/wp-content/uploads/2019/02/amr-sdg-report-final_inter2.pdf)
- 2163 Buie KA, Klugman KP, Gottberg A Von, Perovic O, Karstaedt A, Crewe-brown HH, et al. Gender as a Risk  
2164 Factor for Both Antibiotic Resistance and Infection with Pediatric Serogroups/Serotypes, in HIV-  
2165 Infected and -Uninfected Adults with Pneumococcal Bacteremia. *J Infect Dis*. 2004;189(11):1996–2000.
- 2166 Braveman P. What are health disparities and health equity? we need to be clear. *Public Health Reports*.  
2167 2014;129(SUPPL. 2):5–8.
- 2168 Schröder W, Sommer H, Gladstone BP, Foschi F, Hellman J, Evengard B, et al. Gender differences in  
2169 antibiotic prescribing in the community: A systematic review and meta-analysis. *Journal of*  
2170 *Antimicrobial Chemotherapy*. 2016;71(7):1800–6.
- 2171 Crayton E, Richardson M, Fuller C, Smith C, Liu S, Forbes G, et al. Interventions to improve appropriate  
2172 antibiotic prescribing in long-term care facilities: A systematic review. *BMC Geriatr*. 2020;20(237):1–  
2173 24.
- 2174 Zanichelli V, Tebano G, Gyssens IC, Vlahović-Palčevski V, Monnier AA, Stanic Benic M, et al. Patient-  
2175 related determinants of antibiotic use: a systematic review. Vol. 25, *Clinical Microbiology and Infection*.  
2176 Elsevier B.V.; 2019. p. 48–53.
- 2177 Tricco A, Lillie E Z, W OK, H C, D L, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist  
2178 and explanation. *Ann Intern Med*. 2018;169(7):467–73. Available from: [http://www.prisma-](http://www.prisma-statement.org/Extensions/ScopingReviews)  
2179 [statement.org/Extensions/ScopingReviews](http://www.prisma-statement.org/Extensions/ScopingReviews)
- 2180 World Health Organization. Equitable access to essential medicines: a framework for collective action.  
2181 2004 [cited 2023 Jan 31]. Available from: <https://apps.who.int/iris/handle/10665/68571>
- 2182 Hamadeh N, van Rompaey, Metreau E, Eapen Grace Shwetha. New World Bank country classifications  
2183 by income level: 2022-2023. 2022 [cited 2023 Jan 14]. Available from:  
2184 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)  
2185 [lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
- 2186